(4-isocyanatobutyl)cyclohexane | 787581-11-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (4-isocyanatobutyl)cyclohexane
• 英文别名: Cyclohexane, (4-isocyanatobutyl)-；4-isocyanatobutylcyclohexane
• CAS: 787581-11-7
• 化学式: C₁₁H₁₉NO
• 分子量: 181.278
• InChiKey: XYUAVMLFKNUBGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-isocyanatobutyl)cyclohexane 、 3-(1H-imidazol-4-yl)propanol hydrochloride 在 氨 作用下， 以 乙腈 、 甲醇 、 二氯甲烷 为溶剂， 生成 3-(1H-imidazol-4-yl)propyl 4-cyclohexylbutylcarbamate hydrogen maleate
  参考文献：
  名称：

  N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands

  摘要：

  Previous studies have shown that several imidazole derivatives posses affinity to histamine H-3 and H-4 receptors. Continuing our study on structural requirements responsible for affinity and selectivity for H-3/H-4 receptor subtypes, two series of 3-(1H-imidazol-4-yl) propyl carbamates were prepared: a series of unsaturated alkyl derivatives (1-9) and a series possessing a cycloalkyl group different distances to the carbamate moiety (10-13). The compounds were tested for their affinities at the human histamine H3 receptor, stably expressed in CHO-K1 cells. Compounds 1, 2, 5-7, 10-13 were investigated for their affinities at the human histamine H-4 receptor co-expressed with G alpha(i2) and G beta(1)gamma(2) subunits in Sf9 cells. To expand the pharmacological profile, compounds were further tested for their H3 receptor antagonist activity on guinea pig ileum and in vivo after oral administration to mice. All tested compounds exhibited good affinity for the human histamine H-3 receptor with K-i values in the range from 14 to 194 nM. All compounds were active in vivo after peroral administration (p.o.) to Swiss mice, thus demonstrating their ability to cross the blood-brain barrier. The most potent H-3 receptor ligand of these series was compound 5, 3-(1H-imidazol-4-yl) propyl pent-4-enylcarbamate with the highest affinity (K-i = 14 nM). Additionally, compound 3 showed remarkable central nervous system (CNS) H3R activity, increasing the N-tau-methylhistamine levels in mice with an ED50 value of 0.55 mg/kg, p.o. evidencing therefore, a twofold increase of inverse agonist/antagonist potency compared to the reference inverse agonist/antagonist thioperamide. In this study, the imidazole propyloxy carbamate moiety was kept constant. The different lipophilic moieties connected to the carbamate functionality in the eastern part of the molecule had a range of influences on the human H-4 receptor affinity (154-1326 nM). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.03.046
• 作为产物：
  描述：

  4-环己基-1-丁醇 在 甲烷 、 一水合肼 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 、 乙酸乙酯 为溶剂， 反应 3.0h， 生成 (4-isocyanatobutyl)cyclohexane
  参考文献：
  名称：

  N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands

  摘要：

  Previous studies have shown that several imidazole derivatives posses affinity to histamine H-3 and H-4 receptors. Continuing our study on structural requirements responsible for affinity and selectivity for H-3/H-4 receptor subtypes, two series of 3-(1H-imidazol-4-yl) propyl carbamates were prepared: a series of unsaturated alkyl derivatives (1-9) and a series possessing a cycloalkyl group different distances to the carbamate moiety (10-13). The compounds were tested for their affinities at the human histamine H3 receptor, stably expressed in CHO-K1 cells. Compounds 1, 2, 5-7, 10-13 were investigated for their affinities at the human histamine H-4 receptor co-expressed with G alpha(i2) and G beta(1)gamma(2) subunits in Sf9 cells. To expand the pharmacological profile, compounds were further tested for their H3 receptor antagonist activity on guinea pig ileum and in vivo after oral administration to mice. All tested compounds exhibited good affinity for the human histamine H-3 receptor with K-i values in the range from 14 to 194 nM. All compounds were active in vivo after peroral administration (p.o.) to Swiss mice, thus demonstrating their ability to cross the blood-brain barrier. The most potent H-3 receptor ligand of these series was compound 5, 3-(1H-imidazol-4-yl) propyl pent-4-enylcarbamate with the highest affinity (K-i = 14 nM). Additionally, compound 3 showed remarkable central nervous system (CNS) H3R activity, increasing the N-tau-methylhistamine levels in mice with an ED50 value of 0.55 mg/kg, p.o. evidencing therefore, a twofold increase of inverse agonist/antagonist potency compared to the reference inverse agonist/antagonist thioperamide. In this study, the imidazole propyloxy carbamate moiety was kept constant. The different lipophilic moieties connected to the carbamate functionality in the eastern part of the molecule had a range of influences on the human H-4 receptor affinity (154-1326 nM). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.03.046

文献信息

• [EN] BENZISOTHIAZOL-3-ONE-CARBOXYLIC ACID AMIDES AS PHOSPHOLIPASE INHIBITORS<br/>[FR] AMIDES DE L'ACIDE BENZISOTHIAZOL-3-ONE-CARBOXYLIQUE INHIBITEURS DES PHOSPHOLIPASE
  申请人：LILLY CO ELI

  公开号：WO2004094394A1

  公开（公告）日：2004-11-04

  A novel class of benzisothiazole-3(2H)-one compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases. (I)

  本发明揭示了一类新的苯并异噻唑-3(2H)-酮化合物，以及利用这些化合物抑制肝脂酶和/或内皮脂酶活性，用于治疗、改善或预防肝脂酶和/或内皮脂酶介导的疾病。
• [EN] 3-OXO-1, 3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS<br/>[FR] UTILISATION DE DERIVES AMIDES D'ACIDE 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIQUE COMME INHIBITEURS DE LA PHOSPHOLIPASE
  申请人：LILLY CO ELI

  公开号：WO2004093872A1

  公开（公告）日：2004-11-04

  The present invention provides a compound of formula I (1) wherein; R, is selected from the group consisting of C5-C13alky1;:C,-C,2haloalkyl, C4­C,2alkenyl, C4-C12alkynyl, or C,- C5alkylcycloalkyl, C3-C8cycloalkyl, C,­ C5alkylheterocyclic, and aryl, wherein the, cycloalkyl, cycloalkenyl, heterocyclic and aryl substituents are optionally substituted with onf to three substituents independently selected from C,-C8a)kyl, C,-C8haloalkyl,`C2-CBalkenyl, C2-C8a)kynyl, phenyl, benzyl, hydroxy, C,-C5 alkoxy, (C}12)m000C,-Csalkyl, (CH2)mNRaRb, and C,­C4alkylcycloalkyl; wherein Wand Rb are independently selected from hydrogen, C,­CBalkyl, C2-CBalkenyl, C2-CBalkynyl, and C,- C5alkylcycloalkyl; R2 is hydrogen; R3, R4, R5, and R6, are independently selected from hydrogen, C,-C12alkyl, C2­C,2haloalkyl, C2-C,2 alkenyl, C2-C12alkynyl, C,-Ct2alkylaryl, C,-C12alkylcyclohexyl, C,­ C12alkylcyclopentyl, C,-C1zalkylheterocyclic, (CH2)m000H, (CH2)mC0(C,-C,o)alkyl, (CH2)m COO(C,-C,o)alkyl, (CH2)mCOO(C,-C,o)alkylaryl, C,-C,oalkylamino, halo, (CH2)mCONH2, (CH2)rCONRaRb, phenyl, or aryl wherein each of the phenyl or aryl groups is optionally substituted with one to three groups independently selected from CBalkyl, C,-CBhaloalkyl, C2-CBalkenyl, CZ CBalkynyl, phenyl, benzyl, hydroxy, C,-C5 alkoxy, (CH2)m000C,-Csalkyl, and C,-C4alkylcycloalkyl; and wherein m is 0, 1, 2, or 3; R7 is selected from the group consisting of hydrogen, C,-Cloalkyl, C,­C,ohaloalkyl, C2-C,oalkenyl, C2-C,oalkynyl, C,-C6alkylaryl, C,-C6alkylcyclohexyl, C - C6aikylcyclopentyl, C,-C6alkylheterocyclic, or aryl; or a pharmaceutically acceptable sal lvate thereofi together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase-mediated diseases.

  本发明提供了一种式子I（1）的化合物，其中R选自C5-C13烷基，C3-C12卤代烷基，C4-C12烯基，C4-C12炔基，或C1-C5烷基环烷基，C3-C8环烷基，C1-C5烷基杂环，和芳基，其中环烷基，环烯基，杂环和芳基取代基可选择地独立地被C1-C8烷基，C1-C8卤代烷基，C2-C8烯基，C2-C8炔基，苯基，苄基，羟基，C1-C5烷氧基，（C12）m000C1-C5烷基，（CH2）mNRaRb和C1-C4烷基环烷基取代，其中W和Rb独立地选择氢，C1-C6烷基，C2-C6烯基，C2-C6炔基和C1-C5烷基环烷基；R2为氢；R3、R4、R5和R6独立地选择氢，C1-C12烷基，C2-C12卤代烷基，C2-C12烯基，C2-C12炔基，C1-C12烷基芳基，C1-C12烷基环己基，C1-C12烷基环戊基，C1-C12烷基杂环，（CH2）m000H，（CH2）mCO（C1-C4）烷基，（CH2）mCOO（C1-C4）烷基，（CH2）mCOO（C1-C4）烷基芳基，C1-C4烷基氨基，卤素，（CH2）mCONH2，（CH2）rCONRaRb，苯基或芳基，其中苯基或芳基中的每个取代基可选择地独立地被C1-C8烷基，C1-C8卤代烷基，C2-C8烯基，C2-C8炔基，苯基，苄基，羟基，C1-C5烷氧基，（C12）m000C1-C5烷基和C1-C4烷基环烷基取代；其中m为0、1、2或3；R7选自氢，C1-C6烷基，C1-C6卤代烷基，C2-C6烯基，C2-C6炔基，C1-C6烷基芳基，C1-C6烷基环己基，C1-C6烷基环戊基，C1-C6烷基杂环或芳基；或其药学上可接受的盐；以及使用这样的化合物来抑制肝脏脂肪酶和/或内皮脂肪酶活性，用于治疗、缓解或预防肝脏脂肪酶和/或内皮脂肪酶介导的疾病。
• 3-oxo-1, 3-dihydro-indazole-2-carboxylic acid amide derivatives as phospholipase inhibitors
  申请人：Eacho Irving Patrick

  公开号：US20060211755A1

  公开（公告）日：2006-09-21

  The present invention provides a compound of formula I (1) wherein; R, is selected from the group consisting of C 5 -C 13 alkyl; C,—C, 2 haloalkyl, C 4 C,2alkenyl, C 4 -C 12 alkynyl, or C,—C5alkylcycloalkyl, C3-C8cycloalkyl, C, C 5 alkylheterocyclic, and aryl, wherein the, cycloalkyl, cycloalkenyl, heterocyclic and aryl substituents are optionally substituted with one to three substituents independently selected from C,—C 8 a)kyl, C,—C 8 haloalkyl, ′C 2 -C B alkenyl, C2-C 8 a)kynyl, phenyl, benzyl, hydroxy, C,—C5 alkoxy, (C}12) m 000C,—Csalkyl, (CH2) m NR a R b , and C,C 4 alkylcycloalkyl; wherein W and R b are independently selected from hydrogen, C,C B alkyl, C 2 -C B alkenyl, C 2 -C B alkynyl, and C,—C5alkylcycloalkyl; R 2 is hydrogen; R3, R4, R5, and R6, are independently selected from hydrogen, C,—C 12 alkyl, C 2 C,2haloalkyl, C2-C,2 alkenyl, C 2 -C 12 alkynyl, C,—C 12 alkylaryl, C,—C 12 alkylcyclohexyl, C, C 12 alkylcyclopentyl, C,—C 12 alkylheterocyclic, (CH2) m 000H, (CH2) m C0(C,—C,o)alkyl, (CH 2 ) m COO(C,—C ,o )alkyl, (CH2) m COO(C 1 -C ,o )alkylaryl, C,—C ,o alkylamino, halo, (CH 2 ) m CONH 2 , (CH 2 ) r CONRaR b , phenyl, or aryl wherein each of the phenyl or aryl groups is optionally substituted with one to three groups independently selected from C B alkyl, C,—C B haloalkyl, C 2 -C B alkenyl, C Z C B alkynyl, phenyl, benzyl, hydroxy, C,—C5 alkoxy, (CH2) m 000C,—Csalkyl, and C,—C4alkylcycloalkyl; and wherein m is 0, 1, 2, or 3; R7 is selected from the group consisting of hydrogen, C,—C lo alkyl, C,C ,o haloalkyl, C 2 -C ,o alkenyl, C 2 -C ,o alkynyl, C,—C 6 alkylaryl, C,—C 6 alkylcyclohexyl, C—C 6 aikylcyclopentyl, C,—C 6 alkylheterocyclic, or aryl; or a pharmaceutically acceptable sallvate thereofi together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase-mediated diseases.

  本发明提供一种公式I（1）的化合物，其中：R选自C5-C13烷基；C，C2卤代烷基，C4-C2烯基，C4-C12炔基，或C，C5烷基环烷基，C3-C8环烷基，C，C5烷基杂环基和芳基，其中环烷基，环烯基，杂环和芳基取代基可选地独立地被选自C，C8烷基，C，C8卤代烷基，C2-CB烯基，C2-C8炔基，苯基，苄基，羟基，C，C5烷氧基，（C}12）m000C，C5烷基，（CH2）mNRaRb和C，C4烷基环烷基的一个到三个取代基所取代；其中W和Rb独立地选自氢，C，C8烷基，C2-CB烯基，C2-CB炔基和C，C5烷基环烷基；R2为氢；R3，R4，R5和R6独立地选自氢，C，C12烷基，C2-C，2卤代烷基，C2-C，2烯基，C2-C12炔基，C，C12烷基芳基，C，C12烷基环己基，C，C12烷基环戊基，C，C12烷基杂环基，（CH2）m000H，（CH2）mC0（C，C，o）烷基，（CH2）mCOO（C，C，o）烷基，（CH2）mCOO（C1-C，o）烷基芳基，C，C，o烷基氨基，卤素，（CH2）mCONH2，（CH2）rCONRaRb，苯基或芳基，其中苯基或芳基中的每个苯基或芳基可选地独立地被选自C烷基，C，C卤代烷基，C2-CB烯基，CZCB炔基，苯基，苄基，羟基，C，C5烷氧基，（CH2）m000C，C5烷基和C，C4烷基环烷基的一个到三个基团所取代；其中m为0、1、2或3；R7选自氢，C，C6烷基，C，C6卤代烷基，C2-C，o烯基，C2-C，o炔基，C，C6烷基芳基，C，C6烷基环己基，C-C6烷基环戊基，C，C6烷基杂环基或芳基；或其药学上可接受的盐；以及使用这种化合物来抑制肝脏脂酶和/或内皮脂酶活性，用于治疗、改善或预防肝脏脂酶和/或内皮脂酶介导的疾病。
• Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
  申请人：Eacho Irving Patrick

  公开号：US20060276522A1

  公开（公告）日：2006-12-07

  A novel class of benzisothiazole-3(2H)-one compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases. (I)

  本发明揭示了一种新的苯并异噻唑-3(2H)-酮化合物类别，以及使用这些化合物来抑制肝脂酶和/或内皮脂酶活性，以治疗、改善或预防肝脂酶和/或内皮脂酶介导的疾病。(I)
• Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur
  作者：Koon Mook Kang、Yejin Jang、Sang Soo Lee、Mi Sun Jin、Chang-Duk Jun、Meehyein Kim、Yong-Chul Kim

  DOI：10.1016/j.ejmech.2023.115720

  日期：2023.11

  result, an indole-based derivative, speculated to interact with the S4 binding pocket, 21b (IC50 = 1.5 ± 0.1 μM) was discovered. Its structure was further modified and evaluated in silico by combining docking simulation, free energy perturbation calculation and subpocket interaction analysis to optimize the interactions at the S2 and S4 binding pockets. Among the newly designed novel derivatives, 21h

  严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 主要蛋白酶 (M pro ) 已成为开发针对 COVID-19 感染的抗 SARS-CoV-2 药物的目标，因为 M pro处理必需的病毒多蛋白并发挥关键作用在 SARS-CoV-2 复制中的作用。在这项研究中，我们报告了源自卡莫氟的新型 SARS-CoV-2 M pro抑制剂的开发，卡莫氟是一种先前鉴定的化合物，作为 SARS-CoV-2 M pro的共价抑制剂显示出中等效力。为了采用结构引导的药物设计策略，首先通过对接模拟预测了卡莫氟在 M pro催化活性位点上的假定完整结合模式。基于预测的结合模式，对一系列旨在占据M pro底物结合区域的卡莫氟衍生物进行了构效关系分析。结果， 发现了一种基于吲哚的衍生物，推测与 S4 结合袋相互作用， 21b (IC 50 = 1.5 ± 0.1 μM)。通过结合对接模拟、自由能扰动计算和子口